Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.
about
Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aberrant Signaling through the ...... Lung Cancer (NSCLC) Patients.
@en
Aberrant Signaling through the ...... age Non-Small Cell Lung Cancer
@nl
type
label
Aberrant Signaling through the ...... Lung Cancer (NSCLC) Patients.
@en
Aberrant Signaling through the ...... age Non-Small Cell Lung Cancer
@nl
prefLabel
Aberrant Signaling through the ...... Lung Cancer (NSCLC) Patients.
@en
Aberrant Signaling through the ...... age Non-Small Cell Lung Cancer
@nl
P2093
P2860
P50
P356
P1433
P1476
Aberrant Signaling through the ...... Lung Cancer (NSCLC) Patients.
@en
P2093
Antonia Rizzuto
Cinzia Marinaro
Elvira La Mantia
Giuseppe Viglietto
Nicla De Rosa
Renato Franco
P2860
P304
P356
10.7150/JCA.17093
P50
P577
2017-01-15T00:00:00Z